Duchenne Muscular Dystrophy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Duchenne Muscular Dystrophy - Pipeline Review, H2 2016

Duchenne Muscular Dystrophy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Duchenne Muscular Dystrophy - Pipeline Review, H2 2016
Published Aug 10, 2016
283 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Duchenne Muscular Dystrophy - Pipeline Review, H2 2016, provides an overview of the Duchenne Muscular Dystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy
- The report reviews pipeline therapeutics for Duchenne Muscular Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Duchenne Muscular Dystrophy therapeutics and enlists all their major and minor projects
- The report assesses Duchenne Muscular Dystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measure

  
Source:
Document ID
GMDHC8342IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents214
  List of Tables132
  List of Figures151
Introduction161
  Global Markets Direct Report Coverage161
Duchenne Muscular Dystrophy Overview171
Therapeutics Development182
  Pipeline Products for Duchenne Muscular Dystrophy Overview181
  Pipeline Products for Duchenne Muscular Dystrophy Comparative Analysis191
Duchenne Muscular Dystrophy Therapeutics under Development by Companies205
Duchenne Muscular Dystrophy Therapeutics under Investigation by Universities/Institutes251
Duchenne Muscular Dystrophy Pipeline Products Glance264
  Late Stage Products261
  Clinical Stage Products271
  Early Stage Products281
  Unknown Stage Products291
Duchenne Muscular Dystrophy Products under Development by Companies305
Duchenne Muscular Dystrophy Products under Investigation by Universities/Institutes351
Duchenne Muscular Dystrophy Companies Involved in Therapeutics Development3641
  Acceleron Pharma, Inc.361
  Anagenesis Biotechnology371
  Asklepios BioPharmaceutical, Inc.381
  BioMarin Pharmaceutical Inc.391
  Bristol-Myers Squibb Company401
  Capricor Therapeutics, Inc.411
  Catabasis Pharmaceuticals, Inc.421
  Daiichi Sankyo Company, Limited431
  Debiopharm International SA441
  Editas Medicine, Inc.451
  EryDel SPA461
  FibroGen, Inc.471
  Galapagos NV481
  Genethon491
  GTx, Inc.501
  GW Pharmaceuticals Plc511
  Idera Pharmaceuticals, Inc.521
  Italfarmaco S.p.A.531
  La Jolla Pharmaceutical Company541
  Lexicon Pharmaceuticals, Inc.551
  Marathon Pharmaceuticals, LLC561
  Marina Biotech, Inc.571
  Merck KGaA581
  Milo Biotechnology LLC591
  Mitochon Pharmaceuticals, Inc.601
  MyoTherix Inc.611
  NicOx S.A.621
  Nippon Shinyaku Co., Ltd.631
  Nobelpharma Co., Ltd.641
  Pfizer Inc.651
  Pluristem Therapeutics Inc.661
  Prothelia, Inc.671
  PTC Therapeutics, Inc.681
  RASRx, LLC691
  ReveraGen BioPharma, Inc.701
  Santhera Pharmaceuticals Holding AG711
  Sarepta Therapeutics, Inc.721
  Summit Therapeutics Plc731
  Taiho Pharmaceutical Co., Ltd.741
  WAVE Life Sciences Ltd.751
  Zambon Company S.p.A.761
Duchenne Muscular Dystrophy Therapeutics Assessment7711
  Assessment by Monotherapy Products771
  Assessment by Target783
  Assessment by Mechanism of Action813
  Assessment by Route of Administration842
  Assessment by Molecule Type862
Drug Profiles88178
  4-P001 Drug Profile881
  AAV1-Foliistatin Drug Profile892
  ACE-083 Drug Profile912
  alisporivir Drug Profile933
  Antisense Oligonucleotide 1 to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile961
  Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile971
  Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD Drug Profile981
  Antisense Oligonucleotides to Inhibit ACVR2B for Duchenne Muscular Dystrophy Drug Profile991
  Antisense RNAi Oligonucleotides for Duchenne Muscular Dystrophy Drug Profile1001
  Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders Drug Profile1011
  arbekacin Drug Profile1021
  ARM-210 Drug Profile1032
  AT-300 Drug Profile1052
  ataluren Drug Profile1078
  Biostrophin Drug Profile1151
  BMBD-001 Drug Profile1161
  BMS-986089 Drug Profile1171
  CAP-1002 Drug Profile1185
  CAP-2003 Drug Profile1231
  CAT-1004 Drug Profile1244
  DA-4210 Drug Profile1281
  deflazacort Drug Profile1292
  dexamethasone sodium phosphate Drug Profile1312
  domagrozumab Drug Profile1332
  Drug for Duchenne Muscular Dystrophy Drug Profile1351
  Drugs for Duchenne Muscular Dystrophy Drug Profile1361
  DS-5141 Drug Profile1371
  DT-200 Drug Profile1381
  enobosarm Drug Profile1397
  eteplirsen Drug Profile14611
  ezutromid Drug Profile1576
  Gene Therapy for Duchenne Muscular Dystrophy Drug Profile1631
  Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies Drug Profile1641
  Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile1651
  Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile1661
  Gene Therapy to Activate Utrophin for Duchenne Muscular Dystrophy Drug Profile1671
  givinostat Drug Profile1682
  Gtx-027 Drug Profile1701
  IB-DMD Drug Profile1711
  idebenone Drug Profile1728
  IMO-8400 Drug Profile1806
  LJPC-30Sa Drug Profile1861
  LJPC-30Sb Drug Profile1871
  LX-2931 Drug Profile1882
  MG-53 Drug Profile1902
  MP-101 Drug Profile1921
  Myomir Drug Profile1931
  naproxcinod Drug Profile1943
  NS-065 Drug Profile1971
  Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile1981
  Oligonucleotides 1 to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile1991
  Oligonucleotides 2 to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile2001
  Oligonucleotides 3 to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile2011
  OSX-200 Drug Profile2021
  pamrevlumab Drug Profile2036
  PLX-PAD Drug Profile2099
  poloxamer Drug Profile2182
  PRO-052 Drug Profile2202
  PRO-055 Drug Profile2222
  PRT-01 Drug Profile2242
  Recombinant Protein for Muscular Dystrophy Drug Profile2261
  Recombinant Protein to Activate Utrophin for Muscular Dystrophies Drug Profile2271
  Recombinant Proteins for Duchenne Muscular Dystrophy Drug Profile2281
  rimeporide Drug Profile2291
  RTC-13 Drug Profile2302
  SB-001 Drug Profile2321
  SB-002 Drug Profile2331
  SGT-001 Drug Profile2341
  Small Molecule to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile2351
  Small Molecules for Duchenne Muscular Dystrophy Drug Profile2361
  Small Molecules for Duchenne Muscular Dystrophy Drug Profile2371
  Small Molecules to Activate Utrophin for Duchenne Muscular Dystrophy Drug Profile2381
  Small Molecules to Agonize Cannabinoid Receptor for Duchenne Muscular Dystrophy Drug Profile2391
  SMT-022357 Drug Profile2402
  SRP-4008 Drug Profile2421
  SRP-4044 Drug Profile2431
  SRP-4045 Drug Profile2441
  SRP-4050 Drug Profile2451
  SRP-4052 Drug Profile2461
  SRP-4053 Drug Profile2471
  SRP-4055 Drug Profile2481
  Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile2492
  Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile2511
  Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile2521
  Stryka-516 Drug Profile2531
  Stryka-969 Drug Profile2541
  StrykaPro-1 Drug Profile2551
  Synthetic Peptides for Duchene Muscle Dystrophy Drug Profile2561
  TAS-205 Drug Profile2571
  TVN-102 Drug Profile2581
  TXA-127 Drug Profile2594
  vamorolone Drug Profile2632
  ZP-049 Drug Profile2651
Duchenne Muscular Dystrophy Dormant Projects2664
Duchenne Muscular Dystrophy Discontinued Products2701
Duchenne Muscular Dystrophy Product Development Milestones27111
  Featured News &Press Releases2711
    Jul 25, 2016: PTC Therapeutics Provides Regulatory Update on Translarna (ataluren)2711
    Jul 20, 2016: NICE publishes final guidance recommending ataluren for children with Duchenne muscular dystrophy2712
    Jul 14, 2016: Santhera Updates on U.S. Regulatory Filing for Raxone (idebenone) in Duchenne Muscular Dystrophy2731
    Jul 07, 2016: NHS England Enables Access to Translarna (ataluren) For Patients with Nonsense Mutation Duchenne Muscular Dystrophy2741
    Jul 07, 2016: Catabasis Pharmaceuticals Announces the Initiation of an Open-Label Extension for the MoveDMD Trial Studying Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy2741
    Jun 22, 2016: Pluristem Reports Data Showing PLX-PAD Cells Effective in Treating Duchenne Muscular Dystrophy2751
    Jun 21, 2016: Santhera Marketing Authorization Application for Raxone in Duchenne Muscular Dystrophy (DMD) Validated by the European Medicines Agency2761
    Jun 20, 2016: Catabasis Pharmaceuticals to Present Edasalonexent (CAT-1004), an Oral Agent Targeting NF-kB: MoveDMDSM Trial in Duchenne Muscular Dystrophy at the 2016 PPMD Annual Connect Conference2771
    Jun 17, 2016: First Patient Enrolled in Summit s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMD2771
    Jun 14, 2016: CureDuchenne and Catabasis Pharmaceuticals to Host a Webinar to Review Information on Edasalonexent (CAT-1004) and the MoveDMD Trial on June 22, 20162781
    Jun 14, 2016: Marathon Pharmaceuticals Announces Submission of Deflazacort New Drug Application to the FDA2781
    Jun 08, 2016: Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on MoveDMDSM: A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy2791
    Jun 06, 2016: Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA2791
    May 31, 2016: Santhera Files Marketing Authorization Application in the European Union for Raxone for the Treatment of Duchenne Muscular Dystrophy2801
    May 25, 2016: Sarepta Therapeutics Announces FDA Will Not Complete the Review of the Eteplirsen New Drug Application By The PDUFA Date2811
Appendix2822
  Methodology2821
  Coverage2821
  Secondary Research2821
  Primary Research2821
  Expert Panel Validation2821
  Contact Us2821
  Disclaimer2831

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Duchenne Muscular Dystrophy - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Duchenne-Muscular-Dystrophy-Pipeline-Review-H2-2016-2088-16350>
  
APA:
Global Markets Direct - Market Research. (2016). Duchenne Muscular Dystrophy - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Duchenne-Muscular-Dystrophy-Pipeline-Review-H2-2016-2088-16350>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.